

Coiled-coil irregularities of the M1 protein structure promote M1–fibrinogen interaction and influence group A *Streptococcus* host cell interactions and virulence

Satoshi Uchiyama · Federica Andreoni · Claudia Zürcher ·
Katrin Schilcher · Miriam Ender · Jerzy Madon · Ulrich Matt ·
Partho Ghosh · Victor Nizet · Reto A. Schuepbach ·
Annelies S. Zinkernagel

Received: 13 December 2012 / Revised: 13 February 2013 / Accepted: 15 February 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Group A *Streptococcus* (GAS) is a human pathogen causing a wide range of mild to severe and life-threatening diseases. The GAS M1 protein is a major virulence factor promoting GAS invasiveness and resistance to host innate immune clearance. M1 displays an irregular coiled-coil structure, including the B-repeats that bind fibrinogen. Previously, we found that B-repeat stabilisation generates an idealised version of M1 (M1*) characterised by decreased fibrinogen binding in vitro. To extend these findings based on a soluble truncated version of M1, we now studied the importance of the B-repeat coiled-coil irregularities in full length M1 and M1* expressed in live GAS and tested whether the modulation of M1–fibrinogen interactions would open up novel

Electronic supplementary material The online version of this article (doi:10.1007/s00109-013-1012-6) contains supplementary material, which is available to authorized users.

S. Uchiyama · F. Andreoni · C. Zürcher · K. Schilcher · U. Matt ·
A. S. Zinkernagel (✉)
Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Zurich, University of Zurich, Rämistr 100,
8091 Zurich, Switzerland
e-mail: annelies.zinkernagel@usz.ch

M. Ender · J. Madon · R. A. Schuepbach
Division of Surgical Intensive Care, University Hospital Zurich,
University of Zurich, Zurich, Switzerland

P. Ghosh
Department of Chemistry and Biochemistry,
University of California, San Diego, La Jolla, CA, USA

V. Nizet
Division of Pharmacology and Drug Discovery,
Department of Pediatrics, Skaggs School of Pharmacy
and Pharmaceutical Sciences, University of California, San Diego,
La Jolla, CA, USA

therapeutic approaches. We found that altering either the M1 structure on the GAS cell surface or removing its target host protein fibrinogen blunted GAS virulence. GAS expressing M1* showed an impaired ability to adhere to and to invade human endothelial cells, was more readily killed by whole blood or neutrophils and most importantly was less virulent in a murine necrotising fasciitis model. M1-mediated virulence of wild-type GAS was strictly dependent on the presence and concentration of fibrinogen complementing our finding that M1–fibrinogen interactions are crucial for GAS virulence. Consistently blocking M1–fibrinogen interactions by fragment D reduced GAS virulence in vitro and in vivo. This supports our conclusion that M1–fibrinogen interactions are crucial for GAS virulence and that interference may open up novel complementary treatment options for GAS infections caused by the leading invasive GAS strain M1.

Keywords Group A *Streptococcus* · M protein ·
Fibrinogen · Host cell interactions · Bacterial virulence

Introduction

The Gram-positive bacterium group A *Streptococcus* (GAS) is a leading human pathogen. It causes a substantial disease burden ranging from mild to life-threatening conditions. Annually worldwide, GAS is responsible for >700 million cases of pharyngitis or skin infection and >650,000 invasive infections including necrotising fasciitis (NF) and streptococcal toxic shock syndrome (STSS) [1]. The increasing incidence of severe GAS diseases in recent decades is in large part attributable to the emergence of a globally disseminated clone of the M1T1 serotype [2, 3]. M1T1 strains are the most common

cause of GAS pharyngitis and are strongly overrepresented in severe cases, such as NF and STSS [4].

The M1 protein is a major surface protein and virulence factor expressed by GAS MIT1. M1 contributes to GAS adhesion to host cells [5, 6], provokes inflammation by stimulating macrophages or neutrophils to release cytokines and heparin-binding protein [7–10], and promotes GAS intracellular survival [11]. M1 binds host fibrinogen [12], which can camouflage opsonic targets on the GAS surface to promote evasion of complement-mediated opsonophagocytic killing [13, 14]. Complexes composed of truncated M1 protein shed from the GAS surface and fibrinogen assemble into M1–fibrinogen networks [9], key factors in provoking excessive neutrophil activation and STSS symptoms [10].

Nonideal coiled-coil residues give rise to specific irregularities in the M1 protein's dimeric α -helical coiled-coil structure [7], including the B-repeats which are essential for interactions with fibrinogen. To validate the importance of these irregularities or ‘imperfections’ in the M1 coiled-coil structure to GAS disease pathogenesis, we previously replaced the amino acids alanine responsible for the irregularities of the coiled-coil structure in the B-region to generate an idealised version of the M1 protein (M1*) (Fig. S1a in the Electronic supplementary material (ESM)) [7]. Because a few of the mutated residues were found to make contact to fibrinogen, we then created a second mutant, M1*-R, that contains all the wild-type (WT) fibrinogen-binding residues but is stabilised in register 1. This mutant was as deficient as M1* in binding fibrinogen, indicating that it was the stabilisation of the coiled-coil register M1* rather than the loss of specific amino acids that resulted in poor fibrinogen binding [9]. The recombinant idealised, truncated M1* protein fragment in its soluble form showed greater protein stability but diminished binding to fibrinogen in vitro suggesting that the irregularity of the coiled-coil structure in the B-repeats could contribute to GAS virulence [7]. In the present study, we have now engineered the full length and membrane anchored idealised M1* to be expressed in GAS MIT1 by precise in frame allelic replacement of the *emm1* gene. This mutant GAS strain GAS M1* allowed to assess for the first time the role of the irregular coiled-coil structure in the context of the intact living organism, using tissue culture and small animal models of infection and to test if interference with M1–fibrinogen interaction could open up novel therapeutic approaches.

Materials and methods

Ethics statement

Animal studies C57Bl/6 WT mice were handled in strict accordance with the recommendations in the Guide for the Care

and Use of Laboratory Animals of the National Institutes of Health. The protocol 140/2011 was approved by the Institutional Animal Care and Use Committee of the University of Zurich.

Blood was drawn from healthy volunteers in strict accordance with the institutional guidelines according to Declaration of Helsinki principles. The protocol 2010-0126/0 was approved by the Institutional Review Board of the University of Zurich. Written informed consent was received from all participants.

Bacterial strains

The GAS strain 5448, a well-characterised MIT1 clinical isolate from a patient with necrotising fasciitis and toxic shock syndrome [15], the M protein knockout (GAS Δ M1) [16], and the GASM1* strains in the MIT1 5448 background were propagated in Todd–Hewitt broth (THB; Difco, BD Diagnostics) or THB agar plates.

Engineering of GAS strain expressing idealised M1

The sequence encoding the N-terminal sequence of M1* (1–345aa) was excised from the pET28b vector [7] using the restriction enzymes *XbaI/HindIII* (NEB). The sequence encoding the C-terminal sequence of M1 protein (346–485aa) was excised from the pCR2.1 TOPO vector [16] using restriction enzymes *HindIII/KpnI* (NEB). These two fragments were ligated overnight and the ligated fragment, representing the whole *emm1** gene, was cloned into the pCR2.1 TOPO vector (Invitrogen) at *XbaI* and *KpnI*. Successful cloning and creation of the pCR2.1 TOPO-*emm1** vector was confirmed by sequencing. The CDS encoding *emm1** was then sub-cloned into the temperature sensitive vector pHY304 at *EcoRI* and *BamHI* to give rise to the *pemm1** vector. Electrocompetent GAS M1 5448 cells were transformed with the *pemm1** vector; double crossover events were screened by PCR followed by restriction digest using PVUII, only present in the *emm1** gene. The correct genomic insertion and sequence were verified and confirmed by sequencing.

M protein surface detection by western blot and flowcytometry

GAS strains were grown to OD₆₀₀=0.4 in THB. Western blot was carried out as previously described [17]. Pellets from 1-ml overnight cultures of GAS strains were heated at 90 °C for 10 min in Laemmli buffer followed by separation by SDS page and transfer to PVDF membranes (Millipore). After blocking, the membranes were incubated with a polyclonal rabbit α -M1 antibody followed by incubation with an α -rabbit antibody (Invitrogen). Immunoreactive bands were detected using the Super Signal West Pico chemoluminescent substrate

(Pierce). For flow cytometry, 1 ml of the bacterial culture was pelleted, washed, and resuspended in PBS+10 % BSA for blocking. After washing, the pellet was incubated with the rabbit polyclonal antibody against M1 protein, then resuspended in goat anti-rabbit (FAB) Alexa 488 (Invitrogen), washed and finally resuspended in PBS for FACS analysis.

Fibrinogen-binding measurements by FACS

Fibrinogen (CSD Behring) was labelled with FITC using the FluoReporterR Protein Labeling Kit (Invitrogen) and added to GAS strains grown to $OD_{600}=0.4$ in THB, samples were incubated for 30 min. To measure fibrinogen binding to GAS in the presence of fragment D, fragment D (as prepared in [7]) was added at a concentration of 500 $\mu\text{g/ml}$ together with 50 $\mu\text{g/ml}$ FITC-labelled fibrinogen before FACS analysis (FACSScan, BectonDickinson).

Adherence and invasion assay

Adherence and invasion assays were performed as previously described [18] using the EA.hy926 endothelial cell line [19] grown to confluence in DMEM+10 % FCS and split into 24-well plates and cultivated in DMEM+0.4 % BSA. GAS strains (OD_{600} 0.4) were resuspended in DMEM+0.4 % BSA and added to the endothelial cells at a MOI of 1 for adherence or MOI of 10 for invasion assays. For the fragment D competition assay, either 50 $\mu\text{g/ml}$ fibrinogen (CSL Behring) or 50 $\mu\text{g/ml}$ fibrinogen plus 500 $\mu\text{g/ml}$ fragment D were added and the bacteria were incubated for 30 minutes at 37 °C. The fibrinogen or fibrinogen plus fragment D coated bacteria were used for adherence and invasion assays as described above. To visualise and quantify the adhesion by fluorescence microscopy, EA.hy926 cells were grown on bovine fibronectin-coated (Invitrogen) glass coverslips (Thermo Scientific) in a 24-well plate and challenged with the GAS strains at a MOI of 1. After fixation with 4 % paraformaldehyde and co-incubation with either a polyclonal rabbit anti-GAS or isotype control (R&D Systems) Alexa Fluor® 488F(ab')₂ anti-rabbit IgG (Invitrogen) was used as secondary antibody. DAPI dihydrochloride (Sigma) was then added and glass slides mounted with ProlongGold antifade reagent (Invitrogen). Fluorescence microscopy images were taken using an Olympus inverted microscope IX71 equipped with a mercury burner U-RFL-T as light source, an Olympus XM10 digital camera and a 10 \times /0.30 Ph1 UPlanFLN Olympus objective at calibrated magnifications. Images were taken and identically processed using the CellF imaging software (version 3.2) from Olympus. The fluorescence signal for one field is derived from the sum of grey value intensity

per field. The average background signal was calculated as the mean of ten images of the isotype control. The corrected fluorescence intensity of a field was calculated by subtraction of the average background signal from the fluorescence signal of the field. Means of corrected intensity values of at least five pictures per slide, performed in triplicate, were calculated. Microscope settings were kept constant during image acquisition.

Whole blood and neutrophil killing assays

Whole blood killing assay was performed as previously described with some minor modifications [20]. Ancrod (Serva electrophoresis) was added at a final concentration of 0.1 U/ml to whole blood and the blood with or without Ancrod was incubated for 30 min rotating at 37 °C for defibrinogenisation.

Neutrophil killing assays were performed as previously described with some minor modifications [21]. Human neutrophils were challenged with GAS strains that had been pre-incubated with either 100 $\mu\text{g/ml}$ fibrinogen or 500 $\mu\text{g/ml}$ fragment D alone or with both 50 $\mu\text{g/ml}$ fibrinogen and 500 $\mu\text{g/ml}$ fragment D at an MOI of 1. Neither fibrinogen nor fragment D was added in control samples. To assess extracellular killing, neutrophils were preincubated with 1 μM cytochalasin D (Sigma) for 30 min at 37 °C.

Murine infection model

GAS was injected subcutaneously into the flanks of 10- to 12-week-old C57Bl/6 WT mice [21] purchased from Janvier, France: on the one side GAS M1 on the other side the GAS M1* was injected. Skin lesion sizes were monitored daily for 4 days, then the mice were sacrificed and the bacteria present in the skin lesions enumerated. For the fragment D competition assay, either fragment D at a final concentration of 1.5 mg/ml or PBS as control was added to GAS M1. GAS M1 with fragment D was injected on one side and on the other side GAS M1 without fragment D. Lesions sizes were assessed as described above.

Statistics

Data were analysed and edited using the SPSS (SPSS 11.5 Inc., Chicago, Illinois), the NCSS (Kaysville, Utah), and Graphpad prism 5 software (Graphpad Software Inc, La Jolla, California) packages. Two-sample two-tailed homoscedastic *t* tests or a nonparametric Mann–Whitney *U* test were used to calculate the indicated *p* values. Statistics show *p* values compared with WT in the same group unless indicated by brackets. In vivo data were analysed by two-tailed Wilcoxon signed-rank test for paired samples.

Results

Construction and characterisation of a GAS M1* strain

To explore the effects of the full length and cell surface expressed idealised α -helical coiled-coil protein in the pathogenesis of GAS, the WT M1 protein gene *emm1* was replaced by the *emm1** mutated gene (Fig. S1b in the ESM) by precise allelic replacement. The integrity of this mutation was confirmed by chromosomal DNA sequencing. Expression of M1* and its localisation on the bacterial surface were analysed by western blot and FACS (Fig. 1a, b). No difference in bacterial growth between GAS expressing M1 and M1* was observed (Fig. S2a in the ESM). To control that only M protein was affected and no other GAS virulence factors influencing pathogenicity, the activity levels of the GAS neutrophil resistance factors streptolysin O (SLO) and DNase (Sda1) were assessed and found to be comparable (Fig. S2b, c in the ESM). SLO induces apoptosis in macrophages [22] and DNase degrades NETs [23, 24] which both facilitate GAS to evade the innate immune system.

Reduced fibrinogen binding by GAS M1* resulting in reduced adherence to and invasion of endothelial cells in the presence of fibrinogen

M1 proteins expressed on GAS surface or shed into the supernatant have both been shown to bind host fibrinogen, allowing bacterial camouflage and blunting of the host's innate immune


clearance mechanisms [10]. We thus tested whether the idealisation of the B-repeats in the full length cell surface expressed GAS M1* would result in reduced fibrinogen binding to GAS. The capacity of the GAS strains to bind FITC-labelled fibrinogen was quantified by FACS. We found that GAS M1* bound FITC-fibrinogen less readily than GAS M1 (Fig. 1c, d). The similar M1 protein expression levels found by western blotting and flow cytometry (Fig. 1a, b) make it unlikely that the reduced fibrinogen binding could be caused by decreased surface expression of M1 variants. Lack of M1 (GAS Δ M1) resulted in failure to bind fibrinogen (Fig. 1c, d).

Endothelial cells have been shown to interact with fibrinogen [25]. We thus explored whether fibrinogen coating of GAS would facilitate adherence to and invasion of endothelial cells line EA.hy926. GAS M1 strain displayed significantly higher adherence to and invasion of EA.hy926 cells compared with GAS M1* at ≥ 10 μ g/ml (Fig. 2a, b). These quantitative observations were further corroborated by fluorescence microscopy (Fig. 2c, d).

Reduced fibrinogen binding lowers the ability of GAS M1* to circumvent host innate immune killing

We next examined whether the difference in fibrinogen binding between GAS M1 and GAS M1* affected the ability of host innate immune cells to clear the pathogen. GAS killing assays were performed using human whole blood derived from healthy volunteers. The superior ability of GAS M1 to bind fibrinogen correlated with enhanced

Fig. 1 Characterisation of GAS M1*. Expression of WT M1 (GAS M1) and idealised M1 protein (GAS M1*) in GAS was analysed by western blot (a) and FACS (b). c Binding of FITC-labeled fibrinogen (Fg) to the various GAS strains as analysed by FACS analysis with quantitative analyses given in (d). Representative experiments out of three independent repeats (a–c), pooled from three independent experiments (d)






Fig. 2 Correlation of fibrinogen M1 protein binding with GAS adhesion to and invasion of endothelial cells. **a–d** Human endothelial cells (EA.hy926) were challenged with GAS strains to assess the ability of GAS to **a** adhere to and **b** to invade host cells. GAS strains were pre-incubated with given concentrations of fibrinogen. Increasing fibrinogen concentrations boosted adherence and invasion only in the M1 protein-expressing GAS. **c** Representative bright field and fluorescence microscopy images showing GAS (green) adhering to EA.hy926 cells.


d Quantification of detected fluorescence signal in the absence (control) or presence of fibrinogen (100 µg/ml). Adherence of GAS ΔM1 was independent of fibrinogen, whereas fibrinogen improved adherence of GAS M1 and to a lesser extent of GAS M1*. **a, b** Data were pooled from three independent experiments. Mean±SEM; **p*<0.05; ***p*<0.01. **d** Experiments were performed in triplicate with two independent repeats, presented mean±SD; ***p*<0.01; arbitrary units; scale bar represents 100 µm

survival compared with both the isogenic ΔM1 and M1* mutant strains (Fig. 3a). To test if this enhanced survival was dependent on the presence of fibrinogen, whole blood was fibrinogen depleted by adding the snake venom Ancrod [26]. Fibrinogen depletion rendered GAS M1 as avirulent as the isogenic ΔM1 and M1* strains (Fig. 3a). Since neutrophils are abundant in the blood and are the first phagocytes to respond to a bacterial infection, we performed a GAS neutrophil killing assay. In this assay, addition of fibrinogen exaggerated the difference in survival between GAS M1 and M1* strains; whereas in the absence of fibrinogen, no difference was observed between these two groups (Fig. 3b). The survival of the ΔM1 strain was significantly reduced both in the presence or absence of fibrinogen as expected given the importance of M1 protein for intracellular survival of GAS in neutrophils [11]. In the next step we examined neutrophil extracellular killing employing cytochalasin D to block phagocytosis. The pattern of GAS survival, GAS M1>GAS M1*>GAS ΔM1 in the presence of fibrinogen further established the importance of

fibrinogen binding for GAS resistance to extracellular neutrophil killing in NETs (Fig. 3c). The enhanced NETs killing of the GAS M1 strain reflected our previous finding that GAS M1 protein is necessary to promote bacterial resistance to killing in NETs and that it contributes to resistance to the human cathelicidin antimicrobial peptide LL-37 [16].

The M1 protein diminishes extracellular GAS susceptibility to the antimicrobial peptide cathelicidin, which is a key component of neutrophils extracellular traps (NETs) [16]. Therefore we examined GAS neutrophil extracellular killing by NETs. To examine the survival of GAS exposed to NETs, neutrophils were pre-stimulated with phorbol myristate acetate (PMA) which activates the protein kinase C [27, 28] thereby triggering nearly 100 % of the neutrophils to produce NETs [29]. In the absence of fibrinogen, no difference in killing within NETs was observed between GAS M1 and M1*. However, when the GAS strains were pre-incubated with fibrinogen, GAS M1 was more resistant to NET-mediated killing compared with GAS M1*. In contrast, the GAS strains GAS M1* and ΔM1 which did not

Fig. 3 Fibrinogen binding hinders GAS clearance by the host innate immune system and enhances GAS virulence. **a** Resistance to whole blood killing in the absence (Ancrod+) or presence (Ancrod-) of endogenous fibrinogen. **b** Resistance to neutrophil killing in the absence (*minus sign*) or presence (*plus sign*) of exogenous fibrinogen (*Fg*). **c** Extracellular killing by neutrophils in which phagocytosis was blocked (cytochalasin D) in the absence (*minus sign*) or presence (*plus sign*) of fibrinogen. **d** NETs formation by neutrophils was induced by addition of PMA before the survival of GAS was examined in the absence (*minus sign*) or presence (*plus sign*) of fibrinogen. **e, f** C57Bl/6 mice were infected subcutaneously with GAS M1 and GAS M1* into the opposite flanks. **e** Time course of skin lesions size after GAS M1 and GAS M1* infection. **f** At day 4, the infected skin of the animals shown in (e) was harvested and homogenised to enumerate surviving bacteria. **a–d** Data were pooled from three independent experiments done in triplicate, mean±SEM; * $p<0.05$; ** $p<0.01$; *** $p<0.001$. **e, f** Data were pooled from two independent experiments, $N=11$; * $p<0.05$



bind fibrinogen as well were susceptible to NET-mediated killing independent of fibrinogen (Fig. 3d).


GAS expressing M1* displays reduced virulence in a murine skin infection model

To extend our *in vitro* findings to an *in vivo* model and to directly compare the virulence of GAS M1 and M1* strains C57Bl/6 WT mice were infected subcutaneously with GAS M1 and M1*. The resultant lesion sizes at the site of infection were measured over time and bacterial counts in mice skin homogenates were assessed. The lesion sizes after infection with the GAS M1* strain were significantly smaller than the lesion size caused by GAS M1 (Fig. 3e). In addition, the GAS M1* strain had significantly diminished *in vivo* survival at the site of infection compared with the GAS M1 strain, as calculated by the number of surviving bacteria recovered from the skin homogenates (Fig. 3f).

Interference of fibrinogen fragment D with GAS virulence *in vitro* and *in vivo*

Fibrinogen fragment D is generated by degradation of fibrinogen by plasmin and was shown to interact with the GAS M1 protein [9] and might also interfere with fibrin formation. We hypothesised that fragment D could interfere with the formation of M1–fibrinogen networks on the GAS surface, ultimately resulting in fewer and weaker interactions of GAS with host cells. Indeed, FACS analysis showed that fibrinogen fragment D hinders fibrinogen binding to GAS M1 (Fig. 4a). Coating bacteria with fragment D alone did not have an effect on neutrophil killing (Fig. 4b) while in the presence of both fragment D and intact fibrinogen, fragment D partially but significantly inhibited neutrophil killing (Fig. 4b) as well as adherence to and invasion of endothelial cells by GAS (Fig. 4c, d). When fragment D was added to GAS M1

Fig. 4 Interference of fragment D with fibrinogen binding blunts GAS virulence in vitro and in vivo. **a** GAS surface binding of FITC-labeled fibrinogen (*Fg*) following incubation of GAS M1 with or without the competitor fragment D (*FgD*; 500 µg/ml) analysed by FACS. **b** GAS M1 was pre-incubated with either 50 µg/ml fibrinogen, 500 µg/ml fragment D, or both before neutrophil challenge and analysis of survival. **c** Adhesion to and **d** invasion of EA.hy926 cells by GAS M1 (control), GAS M1 coated with 50 µg/ml *Fg*, or GAS M1 coated with 50 µg/ml fibrinogen plus 500 µg/ml fragment D (*Fg*+*FgD*). **e**, **f** C57Bl/6 mice were infected subcutaneously with GAS WT coated (one flank) or not (other flank) with *FgD*, and the development of lesions over time and amount of surviving GAS at day 4 was analysed. **a**, **d** Representative graphs from three independent experiments. **b**, **c** Data were pooled from three independent experiments. **b–d** Data shown as mean±SEM. **e**, **f** Data were pooled from two independent experiments, $N=12$; * $p<0.05$; ** $p<0.01$; *** $p<0.001$



before subcutaneous injection in our in vivo model, the bacteria were cleared significantly more efficiently (Fig. 4f) corroborating with our in vitro findings. Consistent with abolishing GAS virulence, fragment D led to a trend ($p=0.15$) for smaller skin lesions formed by GAS M1 (Fig. 4e).

Discussion

Using precise allelic replacement technology we engineered a modified GAS M1T1 strain that expresses the idealised M1* protein characterised by a more stable α -helical coiled-coil structure. This novel GAS M1* strain allowed to directly study the importance of M1–fibrinogen interaction for GAS virulence. We show that bacterial virulence depends on both the functionality of the GAS virulence factor M1 as well as on the presence of the host protein fibrinogen.

Our tool set consisting of GAS either expressing M1, expressing a fibrinogen-binding-deficient M1* or the knock

out strain in conjunction with availability of the host protein fibrinogen (either present in the serum or exogenously added) or its depletion (using either washed host cells or by adding Ancrod) allowed for the first time to fulfil an adapted molecular Koch's postulate examining the role of M1 protein–fibrinogen interaction for GAS adherence and invasion, resistance to whole blood and neutrophil killing as well as for virulence in a murine necrotising fasciitis model. Blocking the fibrinogen–M1 protein interaction with fragment D adds novel treatment concepts.

In addition to allowing to directly and specifically analyse the importance of M1–fibrinogen interaction for GAS virulence in vitro and in vivo, our novel tools helped to overcome some limitations of previous models using M1 protein-deficient GAS strains in which the GAS surface may be fundamentally altered due to the absence of this very abundant surface protein. Furthermore, appropriate expression of the modified protein and unspecific effects are major concerns in engineered pathogens: using two independent techniques, western blot and flow cytometry,

we showed comparable cell surface protein expression after successful allelic replacement of *emm1* by *emm1** and excluded differences in growth and expression of two major GAS virulence factors *slo* and *sdal*.

Our novel tools illustrate how tightly entwined host and pathogens are and that both the pathogen as well as the host contributes to virulence. We found that GAS virulence is blunted when either (1) fibrinogen is depleted or when fragment D competes for M1–fibrinogen interaction as well as when (2) the M protein is altered (GAS M1*) or absent (GAS Δ M1). In contrast to GAS MIT1 which harbours a single *emm* gene other less common GAS serotypes express additional fibrinogen-binding proteins on their cell surface such as the serum opacity factor SOF and the M protein-like surface proteins. Thus loss of M protein–fibrinogen interaction in non-M1 GAS strains could, at least in part, be compensated and our findings might thus not be representative for all pathogenic GAS strains.

Fibrinogen has been shown to facilitate leucocytes endothelial cells interactions [25]. We now provide novel evidence that fibrinogen also supports bacterial–endothelial interactions in the presence of the functional GAS fibrinogen receptor M1. Fibrinogen coating GAS facilitated adherence to and invasion of endothelial cells, both factors important for pathogenicity of invasive infections [30, 31]. Fibrinogen at concentrations as low as 10 μ g/ml enhanced GAS virulence when the fibrinogen-binding M1 protein was available. In addition to blood, the extravascular compartment also contains high levels of fibrinogen, in particular during inflammation, further supporting M1–fibrinogen interaction and thus GAS virulence.

Earlier studies described M1–fibrinogen binding as a mechanism allowing GAS bacterial camouflage and blunting of the host's innate immune clearance mechanisms [10]. Our studies of bacterial survival in whole blood or in presence of neutrophil confirm these conclusions and further illustrate that the host protein fibrinogen is required and has to interact with the bacterial virulence factor M protein to result in virulence. Our observations that M1–fibrinogen interactions help GAS to resist NET-mediated neutrophil killing are consistent with previous work showing NETs support bacterial clearance from blood [32] and that M1 protein diminishes extracellular GAS susceptibility to the antimicrobial peptide cathelicidin, a key component of NET [16]. These findings underscore the importance of the native M1 protein structure both for fibrinogen binding and resistance of GAS to the innate immune response.

Combining knowledge on how M1–fibrinogen bind [9] with understanding the relevance of the M1–fibrinogen interaction we tested fragment D known to bind M1 protein but able neither to polymerise nor to mediate adherence to mammalian fibrinogen receptors as a potential therapeutic. As proof of principle we found that fragment D blunts GAS

virulence in vitro and had therapeutic effects in an in vivo necrotising fasciitis model. It however remains to be clarified whether fibrinogen receptors other than M1 bind fragment D [33] not only efficiently but potentially even better than fibrinogen [34].

To conclude, we showed that GAS expressing M1* showed impaired fibrinogen binding resulting in less invasiveness and reduced resistance towards cell and NET-mediated host killing which translated into reduced virulence in a murine necrotising fasciitis model. We further provide novel evidence that interfering with the M1–fibrinogen interaction by adding the exogenous competitor fragment D reduced pathogenicity of GAS MIT1 indicating that competition with or partial blockage of fibrinogen may open up complementary treatment options for life-threatening invasive GAS infections.

Acknowledgements This research was supported by the ‘Stiftung für Medizinische Forschung, University of Zurich’ (ASZ), the Swiss National Foundation (SNF) grant No. 31-130748 (ASZ); ‘Forschungskredit’ and ‘Zentrum für Klinische Forschung’ both from the University of Zurich and SNF # PZ00P3_136639 (RAS) as well as NIH grants AI096837 and AI077780 (VN and PG).

Disclosure The authors declare no conflict of interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. *Lancet Infect Dis* 5:685–694
- Aziz RK, Kotb M (2008) Rise and persistence of global MIT1 clone of *Streptococcus pyogenes*. *Emerg Infect Dis* 14:1511–1517
- Cole JN, Barnett TC, Nizet V, Walker MJ (2011) Molecular insight into invasive group A streptococcal disease. *Nat Rev Microbiol* 9:724–736. doi:10.1038/nrmicro2648
- Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, Schlievert PM (1992) Clonal basis for resurgence of serious *Streptococcus pyogenes* disease in the 1980s. *Lancet* 339:518–521
- Courtney HS, von Hunolstein C, Dale JB, Bronze MS, Beachey EH, Hasty DL (1992) Lipoteichoic acid and M protein: dual adhesins of group A streptococci. *Microb Pathog* 12:199–208
- Wang JR, Stinson MW (1994) M protein mediates streptococcal adhesion to HEp-2 cells. *Infect Immun* 62:442–448
- McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P (2008) Coiled-coil irregularities and instabilities in group A *Streptococcus* M1 are required for virulence. *Science* 319:1405–1408. doi:10.1126/science.1154470
- Pahlman LI, Morgelin M, Eckert J, Johansson L, Russell W, Riesbeck K, Soehnlein O, Lindbom L, Norrby-Teglund A, Schumann RR et al (2006) Streptococcal M protein: a multipotent and powerful inducer of inflammation. *J Immunol* 177:1221–1228
- Macheboeuf P, Buffalo C, Fu CY, Zinkernagel AS, Cole JN, Johnson JE, Nizet V, Ghosh P (2011) Streptococcal M1 protein constructs a pathological host fibrinogen network. *Nature* 472:64–68. doi:10.1038/nature09967

10. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, Flodgaard H, Lindbom L, Bjorck L (2004) M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. *Cell* 116:367–379
11. Staali L, Morgelin M, Bjorck L, Tapper H (2003) *Streptococcus pyogenes* expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. *Cell Microbiol* 5:253–265
12. Whitnack E, Dale JB, Beachey EH (1984) Common protective antigens of group A streptococcal M proteins masked by fibrinogen. *J Exp Med* 159:1201–1212
13. Ringdahl U, Svensson HG, Kotarsky H, Gustafsson M, Weineisen M, Sjobring U (2000) A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. *Mol Microbiol* 37:1318–1326
14. Carlsson F, Sandin C, Lindahl G (2005) Human fibrinogen bound to *Streptococcus pyogenes* M protein inhibits complement deposition via the classical pathway. *Mol Microbiol* 56:28–39. doi:10.1111/j.1365-2958.2005.04527.x
15. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M (2000) Genetic relatedness and superantigen expression in group A *Streptococcus* serotype M1 isolates from patients with severe and nonsevere invasive diseases. *Infect Immun* 68:3523–3534
16. Lauth X, von Kockritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V (2009) M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. *J Innate Immun* 1:202–214. doi:10.1159/000203645
17. Cole JN, McArthur JD, McKay FC, Sanderson-Smith ML, Cork AJ, Ranson M, Rohde M, Itzek A, Sun H, Ginsburg D et al (2006) Trigger for group A streptococcal M1T1 invasive disease. *FASEB J* 20:1745–1747. doi:10.1096/fj.06-5804fje
18. Uchiyama S, Carlin AF, Khosravi A, Weiman S, Banerjee A, Quach D, Hightower G, Mitchell TJ, Doran KS, Nizet V (2009) The surface-anchored NanA protein promotes pneumococcal brain endothelial cell invasion. *J Exp Med* 206:1845–1852. doi:10.1084/jem.20090386
19. Edgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. *Proc Natl Acad Sci U S A* 80:3734–3737
20. Zinkernagel AS, Peyssonnaud C, Johnson RS, Nizet V (2008) Pharmacologic augmentation of hypoxia-inducible factor-1alpha with mimosine boosts the bactericidal capacity of phagocytes. *J Infect Dis* 197:214–217. doi:10.1086/524843
21. Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V (2008) The IL-8 protease SpyCEP/ScpC of group A *Streptococcus* promotes resistance to neutrophil killing. *Cell Host Microbe* 4:170–178. doi:10.1016/j.chom.2008.07.002
22. Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, Karin M, Salvesen GS, Nizet V (2009) Streptolysin O promotes group A *Streptococcus* immune evasion by accelerated macrophage apoptosis. *J Biol Chem* 284:862–871. doi:10.1074/jbc.M804632200
23. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, Feramisco J, Nizet V (2006) DNase expression allows the pathogen group A *Streptococcus* to escape killing in neutrophil extracellular traps. *Curr Biol* 16:396–400. doi:10.1016/j.cub.2005.12.039
24. Sumby P, Barbian KD, Gardner DJ, Whitney AR, Welty DM, Long RD, Bailey JR, Parnell MJ, Hoe NP, Adams GG et al (2005) Extracellular deoxyribonuclease made by group A *Streptococcus* assists pathogenesis by enhancing evasion of the innate immune response. *Proc Natl Acad Sci U S A* 102:1679–1684. doi:10.1073/pnas.0406641102
25. Sriramarao P, Languino LR, Altieri DC (1996) Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces. *Blood* 88:3416–3423
26. Reid HA (1971) Therapeutic defibrination by Ancrod (Arvin). *Folia Haematol Int Mag Klin Morphol Blutforsch* 95:209–215
27. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J Biol Chem* 257:7847–7851
28. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wroblewski SK, Wakefield TW, Hartwig JH, Wagner DD (2010) Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A* 107:15880–15885. doi:10.1073/pnas.1005743107
29. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. *Science* 303:1532–1535. doi:10.1126/science.1092385
30. Amelung S, Nerlich A, Rohde M, Spellerberg B, Cole JN, Nizet V, Chhatwal GS, Talay SR (2011) The FbaB-type fibronectin-binding protein of *Streptococcus pyogenes* promotes specific invasion into endothelial cells. *Cell Microbiol* 13:1200–1211. doi:10.1111/j.1462-5822.2011.01610.x
31. Kaur SJ, Nerlich A, Bergmann S, Rohde M, Fulde M, Zahner D, Hanski E, Zinkernagel A, Nizet V, Chhatwal GS et al (2010) The CXC chemokine-degrading protease SpyCep of *Streptococcus pyogenes* promotes its uptake into endothelial cells. *J Biol Chem* 285:27798–27805. doi:10.1074/jbc.M109.098053
32. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD et al (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. *Nat Med* 13:463–469. doi:10.1038/nm1565
33. Whitnack E, Beachey EH (1985) Inhibition of complement-mediated opsonization and phagocytosis of *Streptococcus pyogenes* by D fragments of fibrinogen and fibrin bound to cell surface M protein. *J Exp Med* 162:1983–1997
34. Schmidt KH, Gerlach D, Kuhnemund O, Kohler W (1984) Quantitative differences in specific binding of fibrinogen fragment D by M-positive and M-negative group-A streptococci. *Med Microbiol Immunol* 173:145–153